{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T04:29:54Z","timestamp":1780633794691,"version":"3.54.1"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007277","name":"Icahn School of Medicine at Mount Sinai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007277","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.ahj.2016.09.006","type":"journal-article","created":{"date-parts":[[2016,9,30]],"date-time":"2016-09-30T09:11:40Z","timestamp":1475226700000},"page":"125-134","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":112,"special_numbering":"C","title":["Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study"],"prefix":"10.1016","volume":"182","author":[{"given":"Usman","family":"Baber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Dangas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Michael","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shamir R.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominick J.","family":"Angiolillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart J.","family":"Pocock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell W.","family":"Krucoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adnan","family":"Kastrati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Magnus","family":"Ohman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe Gabriel","family":"Steg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Badimon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Urooj","family":"Zafar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaya","family":"Chandrasekhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Sartori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Aquino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxana","family":"Mehran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"23","key":"10.1016\/j.ahj.2016.09.006_bb0005","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1161\/CIR.0b013e31823a5596","volume":"124","author":"Levine","year":"2011","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.ahj.2016.09.006_bb0010","first-page":"171","volume":"13","author":"Hamm","year":"2012","journal-title":"G Ital Cardiol"},{"issue":"7","key":"10.1016\/j.ahj.2016.09.006_bb0015","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.ahj.2016.09.006_bb0020","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.ahj.2016.09.006_bb0025","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ahj.2016.09.006_bb0030","first-page":"654","volume":"4","author":"Mehran","year":"2011","journal-title":"JACC Cardiovasc Imaging"},{"issue":"9","key":"10.1016\/j.ahj.2016.09.006_bb0035","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.amjcard.2005.06.056","article-title":"Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes","volume":"96","author":"Rao","year":"2005","journal-title":"Am J Cardiol"},{"issue":"8","key":"10.1016\/j.ahj.2016.09.006_bb0040","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1161\/CIRCULATIONAHA.106.612812","article-title":"Adverse impact of bleeding on prognosis in patients with acute coronary syndromes","volume":"114","author":"Eikelboom","year":"2006","journal-title":"Circulation"},{"issue":"15","key":"10.1016\/j.ahj.2016.09.006_bb0045","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.jacc.2012.06.043","article-title":"A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation)","volume":"60","author":"Kim","year":"2012","journal-title":"J Am Coll Cardiol"},{"issue":"20","key":"10.1016\/j.ahj.2016.09.006_bb0050","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1016\/j.jacc.2014.09.008","article-title":"Second-Generation Drug-Eluting Stent Implantation Followed by 6- Versus 12-Month Dual Antiplatelet Therapy: The SECURITY Randomized Clinical Trial","volume":"64","author":"Colombo","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"15","key":"10.1016\/j.ahj.2016.09.006_bb0055","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1093\/eurheartj\/eht438","article-title":"Duration of dual antiplatelet treatment with clopidogrel and aspirin in patients with acute coronary syndrome","volume":"35","author":"Varenhorst","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2016.09.006_bb0060","article-title":"Six-month versus 24-month dual antiplatelet therapy after implantation of drug eluting stents in patients non-resistant to aspirin: ITALIC, a randomized multicenter trial","author":"Gilard","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.ahj.2016.09.006_bb0065","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1093\/eurheartj\/ehs460","article-title":"Should duration of dual antiplatelet therapy depend on the type and\/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY)","volume":"34","author":"Valgimigli","year":"2013","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.ahj.2016.09.006_bb0070","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1161\/CIRCULATIONAHA.111.059022","article-title":"Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience\/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study","volume":"125","author":"Gwon","year":"2012","journal-title":"Circulation"},{"issue":"13","key":"10.1016\/j.ahj.2016.09.006_bb0075","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.jacc.2015.01.039","article-title":"Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","volume":"65","author":"Giustino","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"9872","key":"10.1016\/j.ahj.2016.09.006_bb0080","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","article-title":"Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial","volume":"381","author":"Dewilde","year":"2013","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ahj.2016.09.006_bb0085","doi-asserted-by":"crossref","first-page":"74","DOI":"10.4244\/EIJV10I1A13","article-title":"Everolimus-eluting versus sirolimus-eluting coronary stents in patients with and without diabetes mellitus","volume":"10","author":"Kang","year":"2014","journal-title":"EuroIntervention"},{"issue":"23","key":"10.1016\/j.ahj.2016.09.006_bb0090","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1016\/j.jacc.2008.01.063","article-title":"Long-term outcomes by clopidogrel duration and stent type in a diabetic population with de novo coronary artery lesions","volume":"51","author":"Brar","year":"2008","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.ahj.2016.09.006_bb0095","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1160\/TH13-01-0004","article-title":"Combined and independent impact of diabetes mellitus and chronic kidney disease on residual platelet reactivity","volume":"110","author":"Baber","year":"2013","journal-title":"Thromb Haemost"},{"issue":"6","key":"10.1016\/j.ahj.2016.09.006_bb0100","doi-asserted-by":"crossref","first-page":"e001683","DOI":"10.1161\/CIRCINTERVENTIONS.115.001683","article-title":"Prevalence and Impact of High Platelet Reactivity in Chronic Kidney Disease: Results From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Registry","volume":"8","author":"Baber","year":"2015","journal-title":"Circ Cardiovasc Interv"},{"issue":"11","key":"10.1016\/j.ahj.2016.09.006_bb0105","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/j.jacc.2009.10.043","article-title":"Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy","volume":"55","author":"Angiolillo","year":"2010","journal-title":"J Am Coll Cardiol"},{"issue":"24","key":"10.1016\/j.ahj.2016.09.006_bb0110","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1161\/CIRCULATIONAHA.109.852749","article-title":"Cardiovascular risk prediction in patients with stable and unstable coronary heart disease","volume":"121","author":"Morrow","year":"2010","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.ahj.2016.09.006_bb0115","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.jcin.2012.07.012","article-title":"Development and validation of a stent thrombosis risk score in patients with acute coronary syndromes","volume":"5","author":"Dangas","year":"2012","journal-title":"JACC Cardiovasc Interv"},{"issue":"9","key":"10.1016\/j.ahj.2016.09.006_bb0120","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.jcin.2013.04.016","article-title":"An updated bleeding model to predict the risk of post-procedure bleeding among patients undergoing percutaneous coronary intervention: a report using an expanded bleeding definition from the National Cardiovascular Data Registry CathPCI Registry","volume":"6","author":"Rao","year":"2013","journal-title":"JACC Cardiovasc Interv"},{"issue":"9906","key":"10.1016\/j.ahj.2016.09.006_bb0125","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1016\/S0140-6736(13)61720-1","article-title":"Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study","volume":"382","author":"Mehran","year":"2013","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.ahj.2016.09.006_bb0130","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","article-title":"Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium","volume":"123","author":"Mehran","year":"2011","journal-title":"Circulation"},{"issue":"13","key":"10.1016\/j.ahj.2016.09.006_bb0135","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.jcin.2016.04.009","article-title":"Time-Dependent Associations Between Actionable Bleeding, Coronary Thrombotic Events, and Mortality Following Percutaneous Coronary Intervention: Results From the PARIS Registry","volume":"9","author":"Baber","year":"2016","journal-title":"JACC Cardiovasc Interv"},{"issue":"4","key":"10.1016\/j.ahj.2016.09.006_bb0140","doi-asserted-by":"crossref","first-page":"256","DOI":"10.7326\/0003-4819-115-4-256","article-title":"Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial","volume":"115","author":"Bovill","year":"1991","journal-title":"Ann Intern Med"},{"issue":"10","key":"10.1016\/j.ahj.2016.09.006_bb0145","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1056\/NEJM199309023291001","volume":"329","year":"1993","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ahj.2016.09.006_bb0150","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ahj.2016.09.006_bb0155","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1409312","article-title":"Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents","author":"Mauri","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2016.09.006_bb0160","series-title":"E9 Statistical Principles for Clinical Trials","author":"Guidance for Industry","year":"1998"},{"issue":"1","key":"10.1016\/j.ahj.2016.09.006_bb0165","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1160\/TH09-06-0378","article-title":"A new oral antiplatelet agent with potent antithrombotic properties: comparison of DZ-697b with clopidogrel a randomised phase I study","volume":"103","author":"Zafar","year":"2010","journal-title":"Thromb Haemost"},{"issue":"8","key":"10.1016\/j.ahj.2016.09.006_bb0170","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1161\/01.ATV.18.8.1342","article-title":"Administration of abciximab during percutaneous coronary intervention reduces both ex vivo platelet thrombus formation and fibrin deposition: implications for a potential anticoagulant effect of abciximab","volume":"18","author":"Dangas","year":"1998","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"15","key":"10.1016\/j.ahj.2016.09.006_bb0175","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/j.jacc.2014.08.008","article-title":"Do current clinical trials meet society's needs?: a critical review of recent evidence","volume":"64","author":"Pocock","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"9985","key":"10.1016\/j.ahj.2016.09.006_bb0180","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1016\/S0140-6736(15)60263-X","article-title":"Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials","volume":"385","author":"Palmerini","year":"2015","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ahj.2016.09.006_bb0185","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJM198907203210301","volume":"321","year":"1989","journal-title":"N Engl J Med"},{"issue":"7329","key":"10.1016\/j.ahj.2016.09.006_bb0190","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","volume":"324","year":"2002","journal-title":"BMJ"},{"issue":"12","key":"10.1016\/j.ahj.2016.09.006_bb0195","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1161\/CIRCULATIONAHA.108.813667","article-title":"Safety of short-term discontinuation of antiplatelet therapy in patients with drug-eluting stents","volume":"119","author":"Eisenberg","year":"2009","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.ahj.2016.09.006_bb0200","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/j.1540-8183.2012.00746.x","article-title":"Safety of temporary and permanent suspension of antiplatelet therapy after drug eluting stent implantation in contemporary \"real-world\" practice","volume":"25","author":"Kovacic","year":"2012","journal-title":"J Interv Cardiol"},{"issue":"9","key":"10.1016\/j.ahj.2016.09.006_bb0205","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.amjcard.2016.02.012","article-title":"Trends in P2Y12 Inhibitor Use in Patients Referred for Invasive Evaluation of Coronary Artery Disease in Contemporary US Practice","volume":"117","author":"Fan","year":"2016","journal-title":"Am J Cardiol"},{"issue":"11","key":"10.1016\/j.ahj.2016.09.006_bb0210","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/j.amjcard.2015.02.049","article-title":"Contemporary Use of Ticagrelor in Interventional Practice (from Blue Cross Blue Shield of Michigan Cardiovascular Consortium)","volume":"115","author":"Karve","year":"2015","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2016.09.006_bb0215","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1161\/CIR.0000000000000404","volume":"134","author":"Levine","year":"2016","journal-title":"Circulation"},{"issue":"37","key":"10.1016\/j.ahj.2016.09.006_bb0220","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1093\/eurheartj\/ehu278","volume":"35","author":"Windecker","year":"2014","journal-title":"Eur Heart J"},{"issue":"23","key":"10.1016\/j.ahj.2016.09.006_bb0225","first-page":"2510","article-title":"Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial","volume":"310","author":"Feres","year":"2013","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.ahj.2016.09.006_bb0230","article-title":"Long-term ticagrelor monotherapy versus standard dual antiplatelet therapy followed by aspirin monotherapy in patients undergoing biolimus-eluting stent implantation: rationale and design of the GLOBAL LEADERS trial","volume":"11","author":"Vranckx","year":"2015","journal-title":"EuroIntervention"},{"issue":"4","key":"10.1016\/j.ahj.2016.09.006_bb0235","first-page":"390","article-title":"Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials","volume":"37","author":"Udell","year":"2016","journal-title":"Eur Heart J"},{"issue":"20","key":"10.1016\/j.ahj.2016.09.006_bb0240","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1016\/j.jacc.2015.03.003","article-title":"Benefits and Risks of Extended Duration Dual Antiplatelet Therapy After PCI in Patients With and Without Acute Myocardial Infarction","volume":"65","author":"Yeh","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"19","key":"10.1016\/j.ahj.2016.09.006_bb0245","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1016\/j.jacc.2016.02.064","article-title":"Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents: Risk Scores From PARIS","volume":"67","author":"Baber","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"16","key":"10.1016\/j.ahj.2016.09.006_bb0250","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1001\/jama.2016.3775","article-title":"Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention","volume":"315","author":"Yeh","year":"2016","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.ahj.2016.09.006_bb0255","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.jacc.2004.09.079","article-title":"Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation","volume":"45","author":"Ong","year":"2005","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.ahj.2016.09.006_bb0260","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jcin.2009.10.033","article-title":"The relationship and threshold of stent length with regard to risk of stent thrombosis after drug-eluting stent implantation","volume":"3","author":"Suh","year":"2010","journal-title":"JACC Cardiovasc Interv"},{"issue":"20","key":"10.1016\/j.ahj.2016.09.006_bb0265","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1093\/eurheartj\/ehu523","article-title":"ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting","volume":"36","author":"Schulz-Schupke","year":"2015","journal-title":"Eur Heart J"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870316302022?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870316302022?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T03:20:39Z","timestamp":1668568839000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870316302022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":53,"alternative-id":["S0002870316302022"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2016.09.006","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2016.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}